{"id":"fd711e32b25a","type":"article","url":"https://hartvaat.nl/2026/01/30/galectine-1-is-een-marker-maar-geen-mediator-van-hfpef/","title":"Galectine-1 is een marker maar geen mediator van HFpEF","title_en":"Galectin-1 Is a Marker but Not a Mediator of Heart Failure With Preserved Ejection Fraction","category":"hypertensie","category_label":"Hypertensie","professions":["cardioloog","internist"],"tags":[],"journal":"Hypertension","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26006","source_url":"https://doi.org/https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26006","authors":[],"significance":6,"published":"2026-01-30","source_date":"2026-01-30","image":"","kennis":[],"congress":"","summary_en":"This study showed that galectin-1 is a biomarker but not a mediator of HFpEF, distinguishing association from causation and cautioning against therapeutic targeting of this immune-related protein.","created":"2026-07-03T10:25:29Z","updated":"2026-07-03T13:24:54Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Het immuunsysteem speelt een steeds duidelijkere rol bij cardiale remodeling bij HFpEF. Galectine-1 was eerder geïdentificeerd als opgereguleerd bij HFpEF. Dit onderzoek toont dat galectine-1 een marker is maar geen mediator van de ziekte.","abstract_original":"Hypertension, Volume 83, Issue 4, Page e26006, April 1, 2026. BACKGROUND:The immune system is emerging as a key player in driving cardiac remodeling in heart failure with preserved ejection fraction (HFpEF). Galectin-1 (Lgals1) is a carbohydrate-binding protein that we previously identified as being upregulated in cardiac myeloid cells in a preclinical model of HFpEF. Our objective was to determine the role of galectin-1 in HFpEF in both preclinical models and clinical cohort studies.METHODS:Galectin-1 was measured using the Olink proximity extension assay in human cohorts. HFpEF was induced in mice with myeloid-specific and global deletion of galectin-1 and corresponding controls using the hypertensive deoxycorticosterone acetate-salt model.RESULTS:Plasma galectin-1 was higher in both a preclinical model of HFpEF (P=0.022) and in patients with heart failure (P<0.001) in the UK Biobank. In patients without heart failure, higher galectin-1 levels were associated with a greater ri"}